Survival Analysis of Carcinoma of the Minor Salivary Gland

Share this content:
Carcinoma of the minor salivary gland prognosis is associated with histologic subtype, tumor subsite, age at the time of diagnosis.
Carcinoma of the minor salivary gland prognosis is associated with histologic subtype, tumor subsite, age at the time of diagnosis.

Carcinoma of the minor salivary gland (MSG) prognosis is associated with histologic subtype, tumor subsite, age at the time of diagnosis, grade, and surgical therapy, according to a study published in JAMA Otolaryngology–Head & Neck Surgery.1

Because there is limited evidence surrounding the prognostic factors of MSG carcinoma available to guide oncologists in counseling patients on the prognosis and management of this type of head and neck cancer, researchers sought to evaluate the 5- and 10-year cause-specific survival rates of MSG carcinomas.

For the study, researchers analyzed data from 5334 patients with MSG carcinoma included in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database.

The most common histologic subtypes were mucoepidermoid carcinoma, adenoid cystic carcinoma, and adenocarcinoma. The most frequent head and neck tumor subsites were the oral cavity and the pharynx.

Results showed that the 5-year cause-specific survival rate was significantly worse for patients with MSG malignant neoplasms in the larynx (HR, 2.42; 95% CI, 1.67 - 3.50) and the nasal cavity and/or paranasal sinus (HR, 1.73; 95% CI, 1.29 - 2.32).

Researchers found that age was also associated with survival. Patients older than 75 years had a significantly worse 5-year cause-specific survival rate (HR, 2.88; 95% CI, 2.05 - 4.06).

RELATED: Dasatinib Active, Well Tolerated in Adenoid Cystic Malignant Salivary Tumors

In terms of positive prognostic factors, local tumor destruction (HR, 0.44; 95% CI, 0.30 - 0.64), partial surgery (HR, 0.33; 95% CI, 0.23 - 0.47), and total surgery (HR, 0.55; 95% CI, 0.41 - 0.74) were each associated with improved 5-year cause specific survival compared with no surgery.

Of note, this is the largest study to date to assess the survival of patients with MSG carcinoma in the United States.

Reference

  1. Baddour Jr HM, Fedewa SA, Chen AY. Five- and 10-year cause-specific survival rates in carcinoma of the minor salivary gland [published online ahead of print December 3, 2015]. JAMA Otolaryngol Head Neck Surg. doi: 10.1001/jamaoto.2015.2805.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters